Carlyle Group
CG
$51.28
-1.50%
The Carlyle Group is one of the world's largest alternative asset managers, operating across global private equity, credit, and investment solutions, with nearly $477 billion in total assets under management. The firm is a dominant player in the private capital industry, distinguished by its scale, global reach across 29 offices, and a diversified platform serving over 3,100 institutional and high-net-worth investors. The current investor narrative is focused on its strategic expansion, as evidenced by the recent multibillion-dollar acquisition of MAI to bolster its wealth management footprint, but this is juxtaposed against significant near-term stock price volatility and concerns over fundraising and realization activity in a challenging macroeconomic environment for private equity.…
CG
Carlyle Group
$51.28
Investment Opinion: Should I buy CG Today?
Rating: Hold. The core thesis is that CG presents a high-risk, high-potential-reward situation where compelling valuation is counterbalanced by severe technical damage and fundamental uncertainty, warranting a wait-and-see approach.
Supporting evidence for this Hold rating includes the stark forward P/E of 8.8x, which implies a massive earnings recovery is priced in. Analyst consensus points to a 28% implied upside to the average target price (based on forward EPS of $6.05 vs. current price). However, this is contrasted by a 27.7% price decline over 3 months, negative $1.73 billion free cash flow, and wildly volatile margins, from 0.1% to 19.4% net margin in consecutive quarters. The stock's 2.04 beta further underscores its suitability only for risk-tolerant investors.
The thesis would upgrade to a Buy if the stock stabilizes above its 52-week low of $34, forward EPS estimates are met or raised in the next quarter, and TTM free cash flow shows material improvement. It would downgrade to a Sell if the stock breaks below $34, the forward EPS estimate is cut meaningfully, or negative free cash flow persists. Relative to its own volatile history and the uncertain sector outlook, the stock is fairly valued at current levels, pricing in significant skepticism but not yet a collapse.
Sign up to view all
CG 12-Month Price Forecast
CG is a battleground stock caught between value and value trap. The forward P/E of 8.8x is compelling but justified given the operational volatility, cash burn, and high market correlation (beta 2.04). The neutral stance reflects the high probability (50%) of a base case where the stock churns. The stance would upgrade to bullish on evidence of earnings stabilization and positive cash flow inflection, likely after the next two quarterly reports. It would turn bearish on a break below $34, which would confirm the technical breakdown and likely precede further fundamental deterioration.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Carlyle Group's 12-month outlook, with a consensus price target around $66.66 and implied upside of +30.0% versus the current price.
Average Target
$66.66
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$41 - $67
Analyst target range
Analyst coverage appears limited with only two analysts providing estimates for revenue and EPS, indicating this large-cap stock may have less consistent institutional research coverage than peers, which can contribute to higher volatility. The consensus leans bullish based on recent institutional ratings, with firms like UBS, TD Cowen, RBC Capital, and Barclays maintaining 'Buy' or 'Overweight' ratings as recently as March 2026, though JP Morgan and Evercore ISI have 'Neutral' stances. The estimated EPS range for the forward period is $5.76 to $6.43, with an average of $6.05, and the estimated revenue range is $5.35 billion to $5.83 billion, averaging $5.56 billion; the wide target spread on both metrics signals high uncertainty around the company's near-term financial performance, likely tied to the unpredictable nature of performance fee revenue.
Bulls vs Bears: CG Investment Factors
The evidence presents a stark conflict between deeply discounted valuation/bullish analyst sentiment and severe technical breakdown/operational volatility. Currently, the bearish evidence from price action and fundamental inconsistency carries more weight, as the market is voting with its feet amid sector-wide concerns. The single most important tension in the investment debate is whether Carlyle's forward P/E of 8.8x represents a compelling value trap or a justified discount for a business facing cyclical earnings pressure and heavy cash burn. The resolution hinges on the company's ability to stabilize its earnings trajectory and demonstrate that the MAI acquisition can drive more predictable fee-related earnings.
Bullish
- Deeply Discounted Forward Valuation: The stock trades at a forward P/E of only 8.8x based on analyst consensus EPS of $6.05, which is a significant discount to its trailing P/E of 26.3x. This low multiple suggests the market has priced in substantial pessimism, offering a high margin of safety if earnings materialize.
- Strong Institutional Analyst Support: Despite recent price weakness, major firms including UBS, TD Cowen, RBC Capital, and Barclays maintain 'Buy' or 'Overweight' ratings as of March 2026. This institutional conviction, anchored on a forward EPS estimate averaging $6.05, provides a counter-narrative to the technical sell-off.
- Strategic Expansion via MAI Acquisition: The recent multibillion-dollar acquisition of MAI is a strategic move to bolster Carlyle's wealth management footprint, diversifying its revenue streams into high-net-worth individuals. This long-term growth initiative is not reflected in the current depressed stock price.
- Robust Scale and Liquidity Position: With nearly $477 billion in total AUM and a current ratio of 15.72, Carlyle possesses immense scale and a fortress balance sheet for liquidity. This financial strength provides resilience to navigate fundraising challenges and volatile markets.
Bearish
- Severe Technical Downtrend and High Volatility: The stock is in a deep correction, down 27.7% over 3 months and trading just 38% above its 52-week low. With a beta of 2.04, it is more than twice as volatile as the market, amplifying downside risk and making it a 'falling knife' in the near term.
- Extremely Volatile and Decelerating Fundamentals: Revenue and earnings are highly lumpy; Q4 2025 revenue grew 98.8% YoY, but this followed a weak Q3. Net margin swung from 0.1% in Q3 to 19.4% in Q4, creating an unreliable growth trajectory that complicates valuation and investor confidence.
- Heavy Cash Burn and Dividend Pressure: Trailing twelve-month free cash flow is deeply negative at -$1.73 billion, indicating heavy capital deployment. This raises concerns about the sustainability of the current dividend, which has a payout ratio of 62.5%, if cash flow does not improve.
- Elevated Financial Leverage: A debt-to-equity ratio of 2.41 indicates significant financial leverage, which is common but risky for asset managers in a rising rate environment. This leverage magnifies risks if fundraising or realization activity remains challenged.
CG Technical Analysis
The prevailing price trend is a sharp and sustained downtrend from early 2026 highs, with the stock down 27.70% over the past 3 months and 15.75% over the past 6 months. The current price of $47.29 sits just 38% above its 52-week low of $34.01, positioning it in the lower quartile of its 52-week range ($34.01 - $69.85), which suggests the stock is in a deep correction phase and may present a value opportunity if fundamentals hold, but also risks being a 'falling knife' amid continued selling pressure. Recent momentum is decisively negative and diverging from a positive longer-term trend; while the stock is up 29.10% over the past year, it has fallen 27.70% over 3 months and posted a mere 0.45% gain over 1 month, indicating a severe breakdown in the prior uptrend, likely driven by sector-wide concerns and disappointing quarterly results. Key technical support is the 52-week low of $34.01, while resistance is the recent breakdown level near the 52-week high of $69.85; a sustained break below $34 would signal a new bear phase, while reclaiming the $60 level is needed to suggest a recovery. The stock's beta of 2.04 indicates it is more than twice as volatile as the broader market, which amplifies both downside risk and potential upside during a rebound, a critical factor for risk-aware investors.
Beta
2.04
2.04x market volatility
Max Drawdown
-34.7%
Largest decline past year
52-Week Range
$34-$70
Price range past year
Annual Return
+45.5%
Cumulative gain past year
| Period | CG Return | S&P 500 |
|---|---|---|
| 1m | +7.1% | +4.6% |
| 3m | -21.9% | +1.4% |
| 6m | -10.3% | +5.6% |
| 1y | +45.5% | +33.5% |
| ytd | -15.7% | +2.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CG Fundamental Analysis
Revenue growth is highly volatile and currently decelerating on a sequential basis; Q4 2025 revenue was $1.84 billion, representing a massive 98.8% year-over-year growth, but this follows a weak Q3 2025 revenue of only $780.5 million, indicating lumpy performance allocations and fund realization income that create an inconsistent growth trajectory. The company is profitable but with significant quarter-to-quarter swings in margins; Q4 2025 net income was $358.1 million with a net margin of 19.4%, a strong recovery from a near-break-even Q3 net income of $0.9 million (0.1% margin), while the gross margin for Q4 was 54.5%, down from 73.5% in Q3, reflecting the variable mix of high-margin fee income versus lower-margin investment gains. The balance sheet shows moderate leverage and strong liquidity but concerning cash flow trends; the debt-to-equity ratio is 2.41, indicating significant financial leverage common for asset managers, and the current ratio is a robust 15.72, but trailing twelve-month free cash flow is deeply negative at -$1.73 billion, suggesting heavy capital deployment into investments and potential dividend funding pressures, though return on equity of 14.0% remains acceptable.
Quarterly Revenue
$1.8B
2025-12
Revenue YoY Growth
+0.98%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$-1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CG Overvalued?
Given net income is positive, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 26.3x, while the forward PE is significantly lower at 8.8x, implying the market expects a substantial earnings recovery, with the forward estimate embedding an EPS of approximately $6.05. Compared to sector averages, Carlyle's trailing PE of 26.3x and Price-to-Sales (PS) ratio of 4.34x are not directly comparable without a provided industry benchmark, but the forward PE of 8.8x appears low for a firm of its stature, potentially reflecting skepticism about achieving those forward estimates or a sector-wide discount. Historically, the stock's own trailing PE has fluctuated wildly, from 6.4x in Q3 2024 to over 6,271x in Q3 2025 during a low-earnings quarter; the current 26.3x is below the Q4 2024 level of 21.4x and well off the highs seen during peak earnings periods, suggesting valuation is not stretched relative to its own history, but is being weighed down by cyclical earnings concerns.
PE
26.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -29x~6272x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced, centered on extreme earnings volatility and cash burn. Net margin swung from 0.1% to 19.4% between Q3 and Q4 2025, making reliable forecasting nearly impossible. The negative $1.73 billion TTM free cash flow raises immediate concerns about capital allocation and dividend sustainability, given a 62.5% payout ratio. Furthermore, revenue concentration in performance fees creates a lumpy, unpredictable income stream that is highly sensitive to exit markets, as seen in the 98.8% YoY revenue growth in Q4 following a weak prior quarter.
Market & Competitive Risks are elevated by the stock's high beta of 2.04, making it a leveraged play on broader market and financial sector sentiment. The stock trades at a forward P/E of 8.8x, which may appear cheap but could compress further if the market loses faith in the $6.05 EPS estimate. Competitive and regulatory pressures in the private equity space, coupled with a challenging environment for fundraising and realizations, could prolong the downturn. The recent MAI acquisition, while strategic, introduces integration and execution risk in a new business segment.
The Worst-Case Scenario involves a continuation of the current downtrend, where failed earnings delivery, sustained negative cash flow, and a worsening macro environment for private equity trigger a re-rate to crisis-level valuations. This could see the stock retest its 52-week low of $34.01, representing a potential loss of approximately 28% from the current price of $47.29. A break below this level could trigger further technical selling, with the maximum drawdown of -34.66% serving as a historical guide for extreme downside.
FAQ
The key risks, in order of severity, are: 1) Fundamental Volatility: Extreme swings in revenue and earnings (98.8% YoY growth in Q4) make the business unpredictable. 2) Financial Strain: Negative $1.73 billion TTM free cash flow pressures capital allocation and the dividend. 3) Market Correlation: A beta of 2.04 means CG's stock will fall more than twice as much as the market in a downturn. 4) Execution Risk: The multibillion-dollar MAI acquisition introduces integration challenges in a new business line.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $45 and $55, as it muddles through with volatile earnings meeting the $6.05 EPS estimate. The Bull Case (30% probability) targets $60 to $70 on successful MAI integration and a market rebound. The Bear Case (20% probability) risks a fall to $34-$40 if earnings miss and support breaks. The base case is most likely, hinging on the critical assumption that forward EPS estimates are not cut significantly in the coming quarters.
CG appears statistically undervalued on a forward basis but fairly valued when considering its risks. The forward P/E of 8.8x is low and suggests the market expects a strong earnings recovery. However, this discount is justified by the company's highly volatile fundamentals (net margin swung from 0.1% to 19.4% in consecutive quarters) and heavy cash burn. Compared to its own history, the current trailing P/E of 26.3x is below peaks but reflective of cyclical trough earnings. The valuation implies the market is skeptical of sustainable, high-quality earnings growth.
CG is a high-risk, high-potential-reward stock that may be a good buy only for very risk-tolerant investors with a long time horizon. The forward P/E of 8.8x offers significant upside if the company meets its $6.05 EPS estimate, implying a 28% gain to a fair value based on that multiple. However, the severe 27.7% 3-month decline, negative $1.73 billion free cash flow, and extreme earnings volatility present substantial downside risk, potentially to the 52-week low of $34 (-28%). It is not suitable for conservative portfolios.
CG is unsuitable for short-term trading due to its high beta (2.04) and current severe downtrend, which could lead to rapid losses. It may be suitable for a long-term (3-5 year) investment only for investors who believe in the firm's scale and strategic shift, and who can withstand significant volatility. The lack of a stable dividend (yield 2.4% with cash flow concerns) and earnings visibility supports a longer horizon to allow its strategic initiatives like the MAI acquisition to bear fruit. A minimum holding period of 18-24 months is suggested to assess the turnaround.